Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | MELK | Q14680 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746234 | 0.88 | CRHR1 (0.57) | CRHR1TRPV1HTR1ADRD2HTR2A | |
| SCHEMBL5489958 | 0.84 | CRHR1 (0.55) | CRHR1TRPV1HTR1ADRD2HTR2A | |
| SCHEMBL5493014 | 0.80 | CRHR1 (0.51) | CRHR1TRPV1CYP1A2CYP2C19PHGDH | |
| SCHEMBL5487814 | 0.80 | CRHR1 (0.53) | CRHR1TRPV1HTR1ADRD2HTR2A | |
| SCHEMBL5495067 | 0.78 | CRHR1 (0.51) | CRHR1 | |
| SCHEMBL5487813 | 0.76 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL2190889 | 0.76 | CRHR1 (0.54) | CRHR1TRPV1HTR1ADRD2HTR2A | |
| SCHEMBL4763636 | 0.74 | CRHR1 (0.56) | CRHR1HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL27624999 | 0.74 | CRHR1 (0.49) | CRHR1TRPV1CYP1A2CYP2C19PHGDH | |
| SCHEMBL27624988 | 0.74 | CRHR1 (0.52) | CRHR1TRPV1HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | claimed |
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | CRHR1 2/4885TRPV1 1281/4885HTR1A 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.